Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy

被引:11
|
作者
Li Yu-feng [1 ,2 ]
Deng Zhi-kui [2 ]
Xuan Heng-bao [2 ]
Zhu Jia-bin [2 ]
Ding Bang-he [2 ]
Liu Xiao-ning [2 ]
Chen Bao-an [1 ]
机构
[1] Southeast Univ, Zhongda Hosp, Dept Haematol, Nanjing 210000, Jiangsu, Peoples R China
[2] First Hosp Huaian, Dept Haematol, Huaian 223300, Jiangsu, Peoples R China
关键词
homoharringtonine; chronic myelogenous leukaemia; long term efficacy; CHRONIC MYELOID-LEUKEMIA; INTERFERON-ALPHA; IMATINIB; RESPONSES; RECOMMENDATIONS; CYTARABINE; I/II;
D O I
10.3760/cma.j.issn.0366-6999.2009.12.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Homoharringtonine (HHT) is effective in treating late stage chronic myelogenous leukaemia (CIVIL), but little is known about long term maintenance during complete cytogenetic response. Long term efficacy and toxicity profiles of low dose HHT were evaluated in this study. Methods One hundred and six patients with CIVIL received 1.5 mg/m(2) of HHT alone by continuous daily infusion for seven to nine days every four weeks. Of 79 patients in the control group, 31 were treated with interferon alpha (IFN-alpha) and 48 with hydroxycarbamide. For 17 patients who failed to achieve cytogenetic response within 12 months' treatment of IFN-alpha, HHT was administered. Quantitative RT-PCR was used to detect the BCR-ABL mRNA expression in 36 Philadelphia positive CML patients enrolled after 2007. Haematological and cytogenetic responses were evaluated in all patients at the 12th month of follow-up. Long term efficacy was assessed in a follow-up with a median time of 54 months (12 months-98 months). Results After 12 months of therapy, cytogenetic response rate of the HHT IFN-a and hydroxycarbamide groups were 39/106, 14/31 and 3/48, and corresponding molecular cytogenetic response rates 6/18, 3/8 and 0. Of the 17 patients who received HHT as salvage treatment, 6 achieved cytogenetic response (3 major). At the 48 months' follow-up, cytogenetic response was maintained in 32/39 patients treated with HHT Patients who had cytogenetic response in HHT group or treated with IFN-a also showed longer median chronic durations, which were 45 months (12 months-98 months) and 49 months (12 months-92 months) respectively, indicating a longer survival time. Conclusions Low dose HHT alone showed considerable short term and long term efficacy in the treatment of late stage CIVIL. It may also be a good choice for patients who have failed imatinib, IFN-a treatment or haematopoietic stem cell transplantation or cannot afford these treatments. Chin Med J 2009;122(12):1413-1417
引用
收藏
页码:1413 / 1417
页数:5
相关论文
共 50 条
  • [21] Chronic Myelogenous Leukemia
    Hasserjian, Robert P.
    CURRENT CANCER THERAPY REVIEWS, 2012, 8 (01) : 3 - 13
  • [22] A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804
    Stone, Richard M.
    Donohue, Kathleen A.
    Stock, Wendy
    Hars, Vera
    Linker, Charles A.
    Shea, Thomas
    DeAngelo, Daniel J.
    Marcucci, Guido
    Bloomfield, Clara D.
    Larson, Richard A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (05) : 859 - 864
  • [23] Current therapy of chronic myelogenous leukemia
    Garcia-Manero, G
    Talpaz, M
    Kantarjian, HM
    INTERNAL MEDICINE, 2002, 41 (04) : 254 - 264
  • [24] Drug therapy of chronic myelogenous leukemia
    Hochhaus, A
    Berger, U
    Reiter, A
    Lahaye, T
    Kreil, S
    Hehlmann, R
    MEDIZINISCHE KLINIK, 2002, 97 : 7 - 15
  • [25] Efficacy of low-dose imatinib in chronic-phase chronic myelogenous leukemia patients
    Kobayashi, Shinichi
    Kimura, Fumihiko
    Kobayashi, Ayako
    Sato, Ken
    Motoyoshi, Kazuo
    ANNALS OF HEMATOLOGY, 2009, 88 (04) : 311 - 315
  • [26] Specific targeted therapy of chronic myelogenous leukemia with imatinib
    Deininger, MWN
    Druker, BJ
    PHARMACOLOGICAL REVIEWS, 2003, 55 (03) : 401 - 423
  • [27] Current perspectives on the therapeutic aspects of chronic myelogenous leukemia
    Bhaskar, Asiem
    Raturi, Kiran
    Dang, Shweta
    Gabrani, Reema
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2014, 24 (10) : 1117 - 1127
  • [28] New Drugs for Chronic Myelogenous Leukemia
    Santos, Fabio P. S.
    Quintas-Cardama, Alfonso
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2011, 6 (02) : 96 - 103
  • [29] Management of Advanced-Phase Chronic Myelogenous Leukemia
    Radich, Jerald P.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (5.5): : 669 - 671
  • [30] Prolonged Chronic Phase of greater than 10 Years of Chronic Myelogenous Leukemia in a Patient With Congenital Human Immunodefeciency Virus Infection
    Setty, Bhuvana A.
    Hayani, Karen C.
    Sharon, Bruce I.
    Schmidt, Mary Lou
    PEDIATRIC BLOOD & CANCER, 2009, 53 (04) : 658 - 660